What is Roth Capital's price target for APLS?

Roth Capital's latest stated price target for Apellis Pharmaceuticals Inc. (APLS) is $31, from its action on Mar 13, 2026.

What is Roth Capital's rating on APLS?

Roth Capital rates APLS Buy, a bullish rating, as of Mar 13, 2026.

When did Roth Capital last change its view on APLS?

On Mar 13, 2026, Roth Capital starts coverage at Buy, price target $31.

Analyst firms · Roth Capital · APLS

Roth Capital APLS price target and rating history

Apellis Pharmaceuticals Inc. (APLS) · Health Care

Roth Capital rates Apellis Pharmaceuticals Inc. (APLS) Buy with a $31 price target, as of its latest action on Mar 13, 2026. It has published 4 rating actions on APLS since September 2021, including 0 upgrades and 2 downgrades. Across 3 firms with a APLS price target in the last 12 months, the median target is $28. Roth Capital's $31 is 11% above that.

Current rating: Buy
Price target: $31
Median target, all firms: $28
Actions on APLS: 4

Roth Capital price target on APLS

Roth Capital price target on APLS, each point a stated target, September 2021 to March 2026.

Every Roth Capital rating on APLS

Mar 13, 2026
InitiateRoth Capital starts coverage at Buy, price target $31
Apr 14, 2022
DowngradeRoth Capital downgrades to Sell from Neutral, price target $40
Nov 29, 2021
DowngradeRoth Capital downgrades to Neutral from Buy, price target $46 to $40
Sep 10, 2021
ReiterateRoth Capital cuts its price target to $46 from $80, keeps Buy

How other firms rate APLS

Each firm's latest rating and stated target in the last 12 months.

Firm	Rating	Price target	Date
Roth Capital	Buy	$31	Mar 13, 2026
Barclays	Equal Weight	$24	Jan 28, 2026
BofA Securities	Buy	$28	Jan 21, 2026

Questions about Roth Capital and APLS

What is Roth Capital's price target for APLS?: Roth Capital's latest stated price target for Apellis Pharmaceuticals Inc. (APLS) is $31, from its action on Mar 13, 2026.
What is Roth Capital's rating on APLS?: Roth Capital rates APLS Buy, a bullish rating, as of Mar 13, 2026.
When did Roth Capital last change its view on APLS?: On Mar 13, 2026, Roth Capital starts coverage at Buy, price target $31.
How does Roth Capital's APLS target compare with other analysts?: Across 3 firms with a APLS price target in the last 12 months, the median target is $28. Roth Capital's $31 is 11% above that.

More APLS rating histories

All Roth Capital ratings APLS news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.